Positive preliminary data from Acarix’s exploratory heart failure study SEISMO


Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application.

Acarix PR SEISMO ENG 210113

Acarix PR SEISMO SWE 210113






About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.